Participação do ácido úrico em doenças neurodegenerativas

  • Celmir Oliveira Vilaça UFF
  • Márcia Cristina Antunes Ribas HUAP
  • Marco Antônio Araujo Leite UFF
  • Raphael Breder UFF
  • Bruno Lima Pessoa HUAP
  • Victor Hugo Bastos UFPI
  • Carlos Eduardo Cardoso Universidade de Vassouras
  • Rosano Fiorelli Universidade de Vassouras
  • Stenio Fiorelli Universidade de Vassouras
  • Giseli Roque de Souza Universidade de Vassouras
  • Adalgiza Mafra Moreno UNIG
  • Silmar Teixeira UFPI
  • Eduardo Jorge Custódio UERJ
  • Marco Orsini Universidade de Vassouras
Palavras-chave: Ácido Úrico, Biomarcadores, Estresse Oxidativo

Resumo

Objetivo. Revisão abordando a correlação entre os níveis de ácido úrico e doenças neurodegenerativas. Método. Revisão não sistemática utilizando a plataforma Google Acadêmico de artigos relacionando os níveis de ácido úrico em doenças neurodegenerativas de alta prevalência. Resultados. Foram utilizados 70 artigos em inglês para confecção desta revisão. Conclusão. O ácido úrico principalmente através de seu efeito antioxidante pode participar da fisiopatologia de diversas condições neurodegenerativas. Sendo um biomarcador de mensuração fácil e de baixo custo estudos sobre o ácido úrico poderão auxiliar no diagnóstico, prognóstico e terapias destas patologias neurodegenerativas.

Métricas

Carregando métricas...

Referências

1.Skinner KA, Parks DA, Khoo NH. Uric Acid Metabolism. Encyclopedia of Life Sciences. Chichester: John Wiley & Sons Ltd; 2006. p1-9.
2.Alvarez-Lario B, Macarrón-Vicente J. Evolution of Uric Acid Metabolism in Humans. Encyclopedia of Life Sciences. Chichester: John Wiley & Sons Ltd; 2013. p1-9.
3.Atya HB, Ali SA, Hegazy MI, El Sharkawi FZ. Urinary Urea, Uric Acid and Hippuric Acid as Potential Biomarkers in Multiple Sclerosis Patients. Indian J Clin Biochem 2017;33:163-70. http://dx.doi.org/10.1007/s12291-017-0661-6
4.Glantzounis G, Tsimoyiannis E, Kappas A, Galaris D. Uric Acid and Oxidative Stress. Curr Pharm Des 2005;11:4145-51. http://dx.doi.org/10.2174/138161205774913255
5.Koch M, Keyser J. Uric acid in multiple sclerosis. Neurol Res 2006;28:316-9. https://doi.org/10.1179/016164106X98215
6.Aydin O, Kurtulus F, Eren E, Ellidag HY, Yılmaz N, Yaman A. Balanced oxidative stress index in spite of decreased uric acid levels in multiple sclerosis patients. Neurochem J 2015;9:153-8. https://doi.org/10.1134/S1819712415020026
7.Al-Khateeb E, Althaher A, Al-Khateeb M, Al-Musawi H, Azzouqah O, Al-Shweiki S, et al. Relation between uric acid and Alzheimer’s disease in elderly Jordanians. J Alzheimer’s Dis 2015;44:859-65. https://doi.org/10.3233/JAD-142037
8.Dujmovic I, Pekmezovic T, Obrenovic R, Nikolić A, Spasic M, Mostarica Stojkovic M, et al. Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis. Clin Chem Lab Med 2009;47:848-53. https://doi.org/10.1515/CCLM.2009.192
9.Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson’s disease risk, diagnosis and prognosis. Biomark Med 2010;4:701-12. https://doi.org/10.2217/bmm.10.94
10.Scott GS, Cuzzocrea S, Genovese T, Koprowski H, Hooper DC. Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci USA 2005;102:3483-8. https://doi.org/10.1073/pnas.0500307102
11.Anderson RF, Harris TA. Dopamine and Uric Acid Act as Antioxidants in the Repair of DNA Radicals: Implications in Parkinson’s Disease. Free Radic Res 2003;37:1131-6. https://doi.org/10.1080/10715760310001604134
12.Amorini AM, Petzold A, Tavazzi B, Eikelenboom J, Keir G, Belli A, et al. Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 2009;42:1001-6. https://doi.org/10.1016/j.clinbiochem.2009.03.020
13.Peng F, Yang Y, Liu J, Jiang Y, Zhu C, Deng X, et al. Low antioxidant status of serum uric acid, bilirubin and albumin in patients with neuromyelitis optica. Eur J Neurol 2012;19:277-83. https://doi.org/10.1111/j.1468-1331.2011.03488.x
14.Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95. https://doi.org/10.1067/mcp.2001.113989
15.Pan M, Gao H, Long L, Xu Y, Liu M, Zou J, et al. Serum uric acid in patients with Parkinson’s disease and vascular parkinsonism: a cross-sectional study. Neuroimmunomodulation 2013;20:19-28. https://doi.org/10.1159/000342483
16.Fang P, Li X, Luo JJ, Wang H, Yang XF. A Double-edged Sword: Uric Acid and Neurological Disorders. Brain Disord Ther 2013;2:211-20. https://doi.org/10.4172/2168-975X.1000109
17.Schlesinger I, Schlesinger N. Uric acid in Parkinson’s disease. Mov Disord 2008;23:1653-7. https://doi.org/10.1002/mds.22139
18.Spitsin S, Markowitz CE, Zimmerman V, Koprowski H, Hooper DC. Modulation of serum uric acid levels by inosine in patients with multiple sclerosis does not affect blood pressure. J Hum Hypertens 2010;24:359-62. https://doi.org/10.1038/jhh.2009.83
19.Edwards NL. The role of hyperuricemia in vascular disorders. Curr Opin Rheumatol 2009;21:132-7. https://doi.org/10.1097/BOR.0b013e3283257b96
20.Peng F, Zhang B, Zhong X, Li J, Xu G, Hu X, et al. Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. Mult Scler J 2008;14:188-96. https://doi.org/10.1177/1352458507082143
21.Sampat R, Young S, Rosen A, Bernhard D, Millington D, Factor S, et al. Potential mechanisms for low uric acid in Parkinson disease. J Neural Transm (Vienna) 2016;123:365-70. https://doi.org/10.1007/s00702-015-1503-4
22.Baker JF, Ralph Schumacher H. Update on gout and hyperuricemia. Int J Clin Pract 2010;64:371-7. https://doi.org/10.1111/j.1742-1241.2009.02188.x
23.Hughes P. The CARI guidelines. Kidney stones epidemiology. Nephrology (Carlton) 2007;12:S26-30. https://doi.org/10.1111/j.1440-1797.2006.00724.x
24.Ferraro PM, Curhan GC. Serum Uric Acid and Risk of Kidney Stones. Am J Kidney Dis 2017;70:158-9. https://doi.org/10.1053/j.ajkd.2017.05.004
25.Tambosco L, Percebois-Macadrré L, Rapin A, Nicomette-Bardel J, Boyer FC. Effort training in Parkinson’s disease: A systematic review. Ann Phys Rehabil Med 2014;57:79-104. https://doi.org/10.1016/j.rehab.2014.01.003
26.Poewe W, Wenning G. The differential diagnosis of Parkinson’s disease. Eur J Neurol 2002;9:23-30. https://doi.org/10.1046/j.1468-1331.9.s3.3.x
27.Lee JE, Song SK, Sohn YH, Lee PH. Uric acid as a potential disease modifier in patients with multiple system atrophy. Mov Disord 2011;26:1533-6. https://doi.org/10.1002/mds.23556
28.Kutzing MK, Firestein BL. Altered Uric Acid Levels and Disease States. Pharmacol Exp Ther 2008;324:1-7. https://doi.org/10.1124/jpet.107.129031
29.Chen X, Wu G, Schwarzschild MA. Urate in Parkinson’s Disease: More Than a Biomarker? Curr Neurol Neurosci Rep 2012;12:367-75. https://doi.org/10.1007/s11910-012-0282-7
30.Kim T-H, Lee J-H. Serum Uric Acid and Nigral Iron Deposition in Parkinson’s Disease: A Pilot Study. PLoS One 2014;9:1-4. https://doi.org/10.1371/journal.pone.0112512
31.Moccia M, Pappatà S, Erro R, Picillo M, Vitale C, Amboni M, et al. Uric acid relates to dopamine transporter availability in Parkinson’s disease. Acta Neurol Scand 2015;131:127-31. https://doi.org/10.1111/ane.12295.
32.Facheris MF, Hicks AA, Minelli C, Hagenah JM, Kostic V, Campbell S, et al. Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson’s disease. J Mol Neurosci 2011;43:246-50. https://doi.org/10.1007/s12031-010-9409-y
33.Andreadou E, Nikolaou C, Gournaras F, Rentzos M, Boufidou F, Tsoutsou A, et al. Serum uric acid levels in patients with Parkinson’s disease: Their relationship to treatment and disease duration. Clin Neurol Neurosurg 2009;111:724-8.
https://doi.org/10.1016/j.clineuro.2009.06.012
34.Huertas I, Jesús S, Lojo JA, García-Gómez FJ, Cáceres-Redondo MT, Oropesa-Ruiz JM, et al. Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson’s disease subtype. PLoS One 2017;12:e0174644.
https://doi.org/10.1371/journal.pone.0174644
35.Vieru E, Köksal A, Mutluay B, Dirican AC, Altunkaynak Y, Baybas S. The relation of serum uric acid levels with l-Dopa treatment and progression in patients with Parkinson’s disease. Neurol Sci 2016;37:743-7. https://doi.org/10.1007/s10072-015-2471-z
36.Annanmaki T, Muuronen A, Murros K. Low plasma uric acid level in Parkinson’s disease. Mov Disord 2007;22:1133-7. https://doi.org/10.1002/mds.21502
37.González-Aramburu I, Sánchez-Juan P, Jesús S, Gorostidi A, Fernández-Juan E, Carrillo F, et al. Genetic variability related to serum uric acid concentration and risk of Parkinson’s Disease. Mov Disord 2013;28:1737-40. https://doi.org/10.1002/mds.25507
38.Annanmaki T, Pohja M, Parviainen T, Hakkinen P, Murros K. Uric acid and cognition in Parkinson’s disease: A follow-up study. Parkinsonism Relat Disord 2011;17:333-7.
https://doi.org/10.1016/j.parkreldis.2011.01.013.
39.Annanmaki T, Pessala-Driver A, Hokkanen L, Murros K. Uric acid associates with cognition in Parkinson’s disease. Parkinsonism Relat Disord 2008;14:576-8.
https://doi.org/10.1016/j.parkreldis.2007.11.001
40.Pellecchia MT, Savastano R, Moccia M, Picillo M, Siano P, Erro R, et al. Lower serum uric acid is associated with mild cognitive impairment in early Parkinson’s disease: a 4-year follow-up study. J Neural Transm (Vienna) 2016;123:1399-402.
https://doi.org/10.1007/s00702-016-1622-6
41.Picillo M, Santangelo G, Moccia M, Erro R, Amboni M, Prestipino E, et al. Serum uric acid is associated with apathy in early, drug-naïve Parkinson’s disease. J Neural Transm (Vienna) 2016;123:371-7. https://doi.org/10.1007/s00702-015-1502-5
42.Moccia M, Picillo M, Erro R, Vitale C, Longo K, Amboni M, et al. Is serum uric acid related to non-motor symptoms in de-novo Parkinson’s disease patients? Parkinsonism Relat Disord 2014;20:772-5. https://doi.org/10.1016/j.parkreldis.2014.03.016
43.Lolekha P, Wongwan P, Kulkantrakorn K. Association between serum uric acid and motor subtypes of Parkinson’s disease. J Clin Neurosci 2015;22:1264-7.
https://doi.org/10.1016/j.jocn.2015.02.015.
44.Uribe-San Martín R, Venegas Francke P, López Illanes F, Jones Gazmuri A, Salazar Rivera J, Godoy Ferńndez J, et al. Plasma urate in REM sleep behavior disorder. Mov Disord 2013;28:1150-1. https://doi.org/10.1002/mds.25441.
45.Rentzos M, Nikolaou C, Anagnostouli M, Rombos A, Tsakanikas K, Economou M, et al. Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg 2006;108:527-31. https://doi.org/10.1016/j.clineuro.2005.08.004
46.Oropesa-Ruiz JM, Huertas-Fernández I, Jesús S, Cáceres-Redondo MT, Vargas-Gonzalez L, Carrillo F, et al. Low serum uric acid levels in progressive supranuclear palsy. Mov Disord 2016;31:402-5. https://doi.org/10.1002/mds.26466
47.Eskandarieh S, Heydarpour P, Minagar A, Pourmand S, Sahraian MA. Multiple Sclerosis Epidemiology in East Asia, South East Asia and South Asia: A Systematic Review. Neuroepidemiology 2016;46:209-21. https://doi.org/10.1159/000444019
48.Hurwitz B. The diagnosis of multiple sclerosis and the clinical subtypes. Ann Indian Acad Neurol 2009;12:226-30. https://doi.org/10.4103/0972-2327.58276
49.Altınkaynak K, Varoğlu AO, Aksoy H, Deniz O, Aksoy A. Serum Uric Acid Levels in Patients with Relapsing-Remitting Multiple Sclerosis. Eur J Gen Med 2009;6:166-9.
50.Moccia M, Lanzillo R, Palladino R, Russo C, Carotenuto A, Massarelli M, et al. Uric acid: A potential biomarker of multiple sclerosis and of its disability. Clin Chem Lab Med 2015;53:753-9. https://doi.org/10.1515/cclm-2014-0744
51.Guerrero AL, Martín-Polo J, Laherrán E, Gutiérrez F, Iglesias F, Tejero MA, et al. Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment. Eur J Neurol 2008;15:394-7. https://doi.org/10.1111/j.1468-1331.2008.02087.x
52.Toncev G, Vesic K, Aleksic D, Lazarevic S. Higher Serum Uric Acid Levels in Multiple Sclerosis Patients after Long-term Interferon Beta Treatment. Serbian J Exp Clin Res 2017;18:227-30. 10.1007/s10072-011-0488-5. 10.1515/sjecr-2016-0052
53.Guerrero AL, Gutiérrez F, Iglesias F, Martín-Polo J, Merino S, Martín-Serradilla JI, et al. Serum uric acid levels in multiple sclerosis patients inversely correlate with disability. Neurol Sci 2011;32:347-50. https://doi.org/10.1007/s10072-011-0488-5.
54.Knapp CM, Constantinescu CS, Tan JH, McLean R, Cherryman GR, Gottlob I. Serum uric acid levels in optic neuritis. Mult Scler 2004;10:278-80. https://doi.org/10.1191/1352458504ms1042oa
55.Min JH, Waters P, Vincent A, Lee S, Y Shin H, H Lee K, et al. Reduced serum uric acid levels in neuromyelitis optica: Serum uric acid levels are reduced during relapses in NMO. Acta Neurol Scand 2012;126:287-91. https://doi.org/10.1111/j.1600-0404.2012.01643.x
56.Euser SM, Hofman A, Westendorp RGJ, Breteler MMB. Serum uric acid and cognitive function and dementia. Brain 2009;132:377-82. https://doi.org/10.1093/brain/awn316
57.Ye BS, Lee WW, Ham JH, Lee JJ, Lee PH, Sohn YH. Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer’s disease biomarker related cognitive decline? Eur J Neurol 2016;23:948-57. https://doi.org/10.1111/ene.12969
58.Hu Q, Liu A, Huang M, Cheng L, Kang H, Xu F, et al. Lower serum uric acid levels in cerebral amyloid angiopathy: a pilot study. Neurol Sci 2014;35:1035-9. https://doi.org/10.1007/s10072-014-1634-7
59.Chen X, Guo X, Huang R, Chen Y, Zheng Z, Shang H. Serum uric acid levels in patients with Alzheimer’s disease: A meta-analysis. PLoS One 2014;9:e94084.
https://doi.org/10.1371/journal.pone.0094084.
60.Viazzi F, Leoncini G, Ratto E, Pontremoli R. Hyperuricemia and renal risk. High Blood Press Cardiovasc Prev 2014;21:189-94. https://doi.org/10.1007/s40292-014-0042-7
61.Arévalo-Lorido JC, Carretero-Gómez J, Robles Pérez-Monteoliva NR. Association between serum uric acid and carotid disease in patients with atherosclerotic acute ischemic stroke. Vascular 2019;27:19-26. https://doi.org/10.1177/1708538118797551
62.Abeles AM. Hyperuricemia, Gout, and Cardiovascular Disease: An Update. Curr Rheumatol Rep 2015;17:13.
https://doi.org/10.1007/s11926-015-0495-2
63.Schiess M, Oh I. Serum Uric Acid and Clinical Progression in Parkinson Disease: potential biomarker for nigrostriatal failure. Arch Neurol 2008;65:698-9. https://doi.org/10.1001/archneur.65.6.698
64.Liu WC, Hung CC, Chen SC, Yeh SM, Lin MY, Chiu YW, et al. Association of Hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2012;7:541-8. https://doi.org/10.2215/CJN.09420911
65.Amaro S, Soy D, Obach V, Cervera A, Planas AM, Chamorro A. A Pilot Study of Dual Treatment With Recombinant Tissue Plasminogen Activator and Uric Acid in Acute Ischemic Stroke. Stroke 2007;38:2173-5. https://doi.org/10.1161/STROKEAHA.106.480699
66.Amaro S, Urra X, Gomez-Choco M, Obach V, Cervera A, Vargas M, et al. Uric Acid Levels Are Relevant in Patients With Stroke Treated With Thrombolysis. Stroke 2011;42:S28-32.
https://doi.org/10.1161/STROKEAHA.110.596528
67.Paganoni S, Zhang M, Zárate AQ, Jaffa M, Yu H, Cudkowicz ME, et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol 2012;259:1923-8.
https://doi.org/10.1007/s00415-012-6440-7
68.Auinger P, Kieburtz K, Mcdermott MP. The relationship between uric acid levels and Huntington’s disease progression. Mov Disord 2010;25:224-8. https://doi.org/10.1002/mds.22907
69.Kocer A, Münevver O, Buse H, Dilek A, Asuman V. Serum Uric Acid Level as a Prognostic Factor in Benign Essential Tremor. BJMMR 2015;7:604-10. https://doi.org/10.9734/BJMMR/2015/15960
70.Lee CY, Yoon JH, Park JH, Hong JY, Sunwoo MK, Kang SY. Uric acid level may not be reduced in essential tremor. Int J Neurosci 2018;128:1163-7. https://doi.org/10.1080/00207454.2018.1492574
Publicado
2018-10-09
Como Citar
Oliveira Vilaça, C., Antunes Ribas, M. C., Araujo Leite, M. A., Breder, R., Lima Pessoa, B., Bastos, V. H., Cardoso, C. E., Fiorelli, R., Fiorelli, S., Roque de Souza, G., Mafra Moreno, A., Teixeira, S., Custódio, E. J., & Orsini, M. (2018). Participação do ácido úrico em doenças neurodegenerativas. Revista Neurociências, 26, 1-22. https://doi.org/10.34024/rnc.2018.v26.9861
Seção
Artigos de Revisão

##plugins.generic.recommendByAuthor.heading##